Enhance your expertise with your measuring software

Discover the training options in our ZEISS Metrology Portal.

Lilly recruits top Swedish researcher in Alzheimer´s

One of Sweden's leading Alzheimer's researchers, Oskar Hansson, has been recruited by pharma giant Eli Lilly and will be moving to the USA.

Öresundsinstitutets vd: Novo Nordisk i aktiekris snarare än företagskris

Nedskärningarna på Novo Nordisk väcker frågor i hela den nordiska life science-sektorn. Men enligt Johan Wessman, vd för det dansk-svenska kunskapscentret Öresu...

QPS Netherlands B.V

Webinar: Automate your processes

Free ZEISS webinar on January 30th, 2025.

Superconductor technology: Contactless working in the laboratory of the future

Automated filling and weighing of freeze-dry containers in the cleanroom with SupraMotion from Festo

From powder to implant

Quality assurance for additively manufactured implants.

A mass flow controller that is silent, fast and cost-effective

Portable ventilator breathing devices, bioreactors or the dosing of inert gases all rely on the highest control dynamics. That is exactly what the proportional ...

Advancing Drug Discovery by Combining Complex In-Vitro Models with AI-Powered 3D/4D Image Analysis

Free webinar organized by ZEISS.

FDA approves new cystic fibrosis therapy

A new treatment for cystic fibrosis has been approved by the U.S. Food and Drug Administration (FDA).

Jan Holmgren to receive award for the development of cholera vaccine

Researcher Jan Holmgren is being awarded for the development of the first effective drinkable cholera vaccine. The award is given by the International Vaccine I...

Your solution for right part positioning

ZEISS OmniFix CT - right part positioning solution to get meaningful measuring results for all part sizes.

Partial court victory for entrepreneur who lost his company

Swedish life science entrepreneur Mikael Kubista has won the first round against a law firm that he, along with other co-owners, sued for negligent advice in co...

Rickard Sandberg on this year’s Nobel Prize in Medicine: ”A key discovery”

The discovery that paved the way for the development of todays mRNA vaccines is the basis for this year’s Nobel Prize in Physiology or Medicine.

ZEISS announces CE mark for CIRRUS PathFinder AI tool with automated OCT assessment

Fully integrated AI decision support tool flags B scans that may require further review, supporting more confident decision making and more efficient patient care.

EMA review confirms a risk of new cancer after CAR-T

CAR-T cancer therapies can, in rare cases, induce secondary cancers. The European Medicines Agency (EMA) now recognises this and requires a warning label to be ...

Introducing ZEISS arivis Pro 4.2

ZEISS arivis software enhances custom microscopy image analysis.

Settlement of cancer allegations against blockbuster drug

French pharmaceutical company Sanofi has reached a principal agreement in the US on around 4,000 of the cases in which its now withdrawn blockbuster heartburn d...

Forskaren in Hagastaden now inagurated

The real estate company Vectura's life science center in Hagastaden, Forskaren, is now inaugurated. The opening was attended by people from the industry, politi...

Bio Europe to Stockholm – ”The Swedish ecosystem is now taking the opportunity”

The international life science conference Bio Europe is coming to Sweden for the first time in November. The conference, whose program takes inspiration from AB...

Abbvie förvärvar lovande projekt inom psykisk ohälsa

Abbvie köper ett läkemedelsprogram inom mental hälsa i en miljardaffär som ser lite annorlunda än vad som tidigare uppgetts.

Nytt samarbete: Chat GPT flyttar in i Lundbecks laboratorier

Den danska läkemedelskoncernen Lundbeck tar hjälp av Open AI för att påskynda forskning och effektivisera arbetet inom hela verksamheten.

KI’s freezer fiasco investigated: A chain of failures

A chain of combined technical and organisational shortcomings caused the freezer breakdown at the Karolinska Institute during the Christmas holidays, destroying...

Positive EMA Decision for BioArctic's New Drug Candidate

Bioarctic's drug candidate for multiple system atrophy, exidavnemab, is recommended to be classified as an orphan drug, according to the European Medicines Agency (EMA).